Ross L. Levine: Publications

Share

Dunbar A.J., Bowman R.L., Park Y.C., O’Connor K., Izzo F., Myers R.M., Karzai A., Zaroogian Z., Kim W.J., Fernandez-Maestre I., Waarts M.R., Nazir A., Xiao W., Codilupi T., Brodsky M., Farina M., Cai L., Cai S.F., Wang B., An W., Yang J.L., Mowla S., Eisman S.E., Hanasoge Somasundara A.V., Glass J.L., Mishra T., Houston R., Guzzardi E., Martinez Benitez A.R., Viny A.D., Koche R.P., Meyer S.C., Landau D.A., Levine R.L. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov. 2024 Jan 12. doi: 10.1158/2159-8290.CD-22-0952. Epub ahead of print.

Stonestrom A.J., Menghrajani K.N., Devlin S.M., Franch-Expósito S., Ptashkin R.N., Patel S.Y., Spitzer B., Wu X., Jee J., Sánchez Vela P., Milbank J.H., Shah R.H., Mohanty A.S., Brannon A.R., Xiao W., Berger M.F., Mantha S., Levine R.L. High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer. Blood Adv. 2024 Feb 27;8(4):846-856. doi: 10.1182/bloodadvances.2023011262. PMCID: PMC10875331.

Perner F., Stein E.M., Wenge D.V., Singh S., Kim J., Apazidis A., Rahnamoun H., Anand D., Marinaccio C., Hatton C., Wen Y., Stone R.M., Schaller D., Mowla S., Xiao W., Gamlen H.A., Stonestrom A.J., Persaud S., Ener E., Cutler J.A., Doench J.G., McGeehan G.M., Volkamer A., Chodera J.D., Nowak R.P., Fischer E.S., Levine R.L., Armstrong S.A., Cai S.F. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15. PMCID: PMC10157896.

Dunbar A.J., Kim D., Lu M., Farina M., Bowman R.L., Yang J.L., Park Y., Karzai A., Xiao W., Zaroogian Z., O’Connor K., Mowla S., Gobbo F., Verachi P., Martelli F., Sarli G., Xia L., Elmansy N., Kleppe M., Chen Z., Xiao Y., McGovern E., Snyder J., Krishnan A., Hill C., Cordner K., Zouak A., Salama M.E., Yohai J., Tucker E., Chen J., Zhou J., McConnell T., Migliaccio A.R., Koche R., Rampal R., Fan R., Levine R.L., Hoffman R. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023 May 18;141(20):2508-2519. doi: 10.1182/blood.2022015418. PMCID: PMC10273167.

Miles L.A., Bowman R.L., Merlinsky T.R., Csete I.S., Ooi A.T., Durruthy-Durruthy R., Bowman M., Famulare C., Patel M.A., Mendez P., Ainali C., Demaree B., Delley C.L., Abate A.R., Manivannan M., Sahu S., Goldberg A.D., Bolton K.L., Zehir A., Rampal R., Carroll M.P., Meyer S.E., Viny A.D., Levine R.L. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020 Nov;587(7834):477-482. doi: 10.1038/s41586-020-2864-x. Epub 2020 Oct 28. PMCID: PMC7677169.